MedTrace Logo

Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers

NCT03824171 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-08-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects

Conditions

Interventions

DRUG

Raloxifene 60mg/Cholecalciferol 800IU

Raloxifene 60mg/Cholecalciferol 800IU tablet

DRUG

AD-102

AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2019-03-27
Completion
2019-04-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824171 on ClinicalTrials.gov